genetically-modified neural stem cells expressing e.coli cytosine deaminase
Cell therapyexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2000 (NCT00005796)
Timeline
Indications
Mechanism of action
- Stem CellImmunity, active
Stem Cell immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- genetically-modified neural stem cells expressing e.coli cytosine deaminase
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01172964 | N/A | Aug 1, 2010 | City of Hope National Medical Center |
| NCT00006033 | Phase 2 | Jun 1, 2000 | National Cancer Institute (NCI), University of South Florida |
| NCT00005796 | Phase 1 | Feb 1, 2000 | Indiana University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Indiana University | Academic/Hospital | 1 | 1 | 1 | 2000 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2000 |
| University of South Florida | Academic/Hospital | 1 | 1 | 1 | 2000 |
4 organizations
Page 1 / 1